Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 10/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.38 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.37 |
| ▸ | CHRNG | P07510 | 2/20 | 0.37 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.37 |
| ▸ | CHRND | Q07001 | 2/20 | 0.37 |
| ▸ | FABP4 | P15090 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22443560 | 1.00 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3HSD17B2CHRNA1 | |
| SCHEMBL22443387 | 1.00 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3HSD17B2CHRNA1 | |
| SCHEMBL11112964 | 1.00 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3HSD17B2CHRNA1 | |
| SCHEMBL22453829 | 1.00 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3HSD17B2CHRNA1 | |
| SCHEMBL22453814 | 0.92 | HSD17B2 (0.39) | SLC6A2SLC6A4SLC6A3HSD17B2CHRNA1 | |
| SCHEMBL22443692 | 0.92 | HSD17B2 (0.39) | SLC6A2SLC6A4SLC6A3HSD17B2CHRNA1 | |
| SCHEMBL22443693 | 0.92 | HSD17B2 (0.39) | SLC6A2SLC6A4SLC6A3HSD17B2CHRNA1 | |
| SCHEMBL7614277 | 0.92 | HSD17B2 (0.39) | SLC6A2SLC6A4SLC6A3HSD17B2CHRNA1 | |
| SCHEMBL22443691 | 0.92 | HSD17B2 (0.39) | SLC6A2SLC6A4SLC6A3HSD17B2CHRNA1 | |
| SCHEMBL31010984 | 0.92 | HSD17B2 (0.39) | SLC6A2SLC6A4SLC6A3HSD17B2CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152004-A1 | HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2022-05-19 | — | — | US | disclosed |
| WO-2020188301-A1 | HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220152004-A1 | HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | GPR119, SLC5A1, SLC5A2 | SLC6A2 1338/4885SLC6A4 1655/4885SLC6A3 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.